Sunday 8 November 2026 Export SVA’s income statement to Excel — free account

Sinovac Biotech, Ltd.

Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.

6.47 0.00 0.00%

Follow SVA

Alert me

Market cap: $642.4M
P/E: 0.2×
Fwd P/E: −3.8×
Dividend yield: —
F-score: 3/9
Altman Z: 1.22
Beneish M: −2.38
Dividend safety: 20/100

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 39.83%

Capital & Financial Ratios $m

Size

Market Cap 642.44

Revenue ttm 10,026.00

Net income ttm (83.89)

Free cash flow ttm (786.38)

Net debt Q (5,818.33)

Valuation

P/E 0.19

Forward P/E (3.81)

Price / sales 0.06

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.10

Financial health

Current ratio Q 6.07

Debt / equity Q 0.06

Interest coverage Q 0.00

Growth

Revenue growth Q −98.73%

Operating income growth Q +583.68%

EPS, this year —

EPS, next year A —

Revenue, next year A −99.95%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11,024	10,216	6,640	6,200
Receivables	425	316	313	294
Inventory	136	97	94	107
Other	—	—	—	—
	11,597	10,645	7,064	6,624

	2023	2024	2025	Q'26
Payables	989	803	605	250
ST’ Debt	76	212	229	148
Other	2	2	3	5
	1,293	1,452	1,540	1,091

Compound Annual Growth %

	10y	5y	3y
Sales	19.07%	(5.44%)	(36.29%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	46.92%	41.69%	(20.46%)

Earnings Trends EPS, adjusted, against the consensus

Sep 2015 Estimate −0.02 Actual −0.03

−0.06 −0.04 −0.01 0.02 0.04

Sep 2014 Beat +0.05

Mar 2015 Miss −0.06

Jun 2015 Beat +0.04

Sep 2015 Miss −0.01

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Sep 2014	−0.05	0.00	Beat by 0.05
Mar 2015	0.02	−0.04	Miss by 0.06
Jun 2015	−0.01	0.03	Beat by 0.04
Sep 2015	−0.02	−0.03	Miss by 0.01

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.83)
’24	—	—	—	—	1.27
’23	—	—	—	—	(0.19)
’22	—	—	—	—	1.00
’21	—	—	—	—	74.27
’20	(0.07)	(0.05)	0.10	0.96	0.97

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	386
’24	—	—	—	—	361
’23	—	—	—	—	470
’22	—	—	—	—	1,493
’21	—	—	—	—	19,375
’20	15	52	115	327	511

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(322)	—	—	—
’25	—	(311)	—	—	(512)
’24	—	(439)	—	—	(57)
’23	—	—	—	—	139
’22	—	—	—	—	(771)
’21	—	—	—	—	15,353
’20	(18)	2	14	481	479

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(341)	—	—	—
’25	—	(337)	—	—	(561)
’24	—	(496)	—	—	(154)
’23	—	(93)	—	—	(18)
’22	—	(279)	—	152	(1,174)
’21	—	(431)	—	6,265	14,633
’20	(21)	(31)	(19)	423	352

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	72	174	230	246	511	19,375	1,493	470	361	386	10,026		+20.4%	0	—	—	(99.9%)
	Gross margin, %	69.08	88.39	89.23	86.80	86.84	94.47	54.15	68.77	61.07	67.87	86.90		(1.2) pt	Powerpack Sinovac Biotech, Ltd.’s next three years, line by line Analysts expect revenue to shrink 99.9% a year to 2028 — slower than the 20.4% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	0	45	47	71	217	17,563	25	(84)	43	(262)	7,362		+105.9%
	EBT margin, %	(0.54)	25.84	20.28	28.78	42.42	90.65	1.69	(17.97)	11.85	(67.90)	73.43		(67.4) pt
	Net income	(3)	37	36	65	185	14,459	88	(121)	41	(199)	(84)		+59.0%
Per share, $
Per share, $	Revenue	1.27	3.06	3.55	2.59	5.16	195.09	15.00	6.55	5.03	5.37	0.00		+17.4%
	Earnings	(0.01)	0.45	0.34	0.42	1.06	85.20	1.08	(0.19)	1.27	(0.83)	34.37		+63.4%
	Cash flow	(0.27)	1.05	0.12	0.41	4.85	154.59	(7.75)	1.93	(0.79)	(7.13)	0.00		+43.8%
	Capex	(0.22)	(0.21)	(0.09)	(0.11)	(1.29)	(7.25)	(4.05)	(2.17)	(1.36)	(0.68)	0.00		+13.2%
	Free cash flow	(0.49)	0.84	0.04	0.30	3.56	147.34	(11.79)	(0.24)	(2.15)	(7.81)	0.00		+35.9%
	Book value	2.28	3.11	4.51	3.71	11.33	139.72	127.76	162.08	143.24	89.01	0.00		+50.3%
	Shares, m	57	57	65	95	99	99	100	72	72	72	100		+2.6%
Valuation, ×
Valuation, ×	P/E	0.00	13.59	19.77	16.18	6.05	0.07	0.08	0.19	0.19	0.19	0.19		5.6
	P/S	4.64	1.95	1.96	2.49	1.25	0.03	0.03	0.06	0.06	0.06	0.06		1.3
	P/B	2.59	3.03	1.54	1.74	0.57	0.07	0.07	0.05	0.06	0.10	0.10		1.0
	EV/Sales	4.30	1.63	1.25	1.69	(0.99)	(0.64)	(0.51)	(1.02)	(0.96)	(0.88)	(0.52)		0.4
	EV/FCF	(11.08)	8.03	121.62	14.58	(1.43)	(0.83)	(0.76)	(2.17)	12.01	12.47	6.59		15.2
Cash, $m
Cash, $m	Operating cash flow	(15)	60	8	39	479	15,353	(771)	139	(57)	(512)	(590)		+47.5%
	Capex	(13)	(12)	(6)	(11)	(128)	(720)	(403)	(156)	(97)	(49)	(196)		+16.2%
	Free cash flow	(28)	48	2	28	352	14,633	(1,174)	(18)	(154)	(561)	(786)		+39.5%
Balance, $m
Balance, $m	Working capital	64	111	226	262	881	12,502	11,035	10,305	9,193	5,524	5,533		+64.0%
	Net debt	(25)	(76)	(163)	(199)	(1,144)	(13,406)	(11,309)	(10,770)	(9,840)	(6,145)	(5,818)		+84.6%
	Shareholders’ equity	130	177	292	352	1,120	13,876	12,713	11,642	10,293	6,396	6,465		+54.2%
Returns, %
Returns, %	ROA	(0.29)	10.11	6.51	9.68	8.87	90.74	0.70	(0.10)	0.70	(0.57)	0.00		(0.3) pt
	ROIC	0.30	28.04	22.00	27.93	0.00	2,332.85	(20.75)	(51.13)	(69.65)	(121.75)	0.00		(122.0) pt
	ROE	(0.45)	16.82	9.29	12.36	14.18	112.85	0.81	(0.11)	0.83	(0.72)	0.00		(0.3) pt
People
People	Employees	835	800	870	1,043	2,212	5,505	4,275	3,261	2,643	3,008	—		+15.3%
	Revenue/emp, $m	0.09	0.22	0.26	0.24	0.23	3.52	0.35	0.14	0.14	0.13	—		+4.4%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2020 · fundamentals updated 26 Oct 2026

No peers yet.

Sinovac Biotech, Ltd. (SVA) Latest News

17 Aug

Impact 3 · 8:00 AM

SINOVAC Reports Unaudited First Half of 2026 Financial Results

15 Jun

Impact 4 · 6:00 AM

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements

29 May

Impact 4 · 4:01 PM

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report

8 May

Impact 3 · 5:00 PM · Business Wire

SINOVAC Reports Unaudited First Half of 2025 Financial Results

6 Feb

Impact 3 · 5:17 AM · GlobeNewswire

Coxsackievirus Infections Market Research Report 2025-2035: High Burden of Pediatric and Neonatal Infections, Link to Type 1 Diabetes Risk, Advances in Vaccine Development Driving Expansion

22 Jan

Impact 3 · 6:00 AM · Business Wire

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

4 Jan

Impact 3 · 10:13 AM

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

17 Dec

Impact 4 · 7:00 AM · Business Wire

Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting

18 Nov

Impact 4 · 3:00 PM · Business Wire

SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

11 Nov

Impact 3 · 5:00 PM · PR Newswire

Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment

24 Oct

Impact 3 · 10:30 AM · Business Wire

SINOVAC Announces Appointment of Independent Auditor

11 Jul

Impact 4 · 4:21 PM · Business Wire

SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

10 Jul

Impact 3 · 7:23 AM

Newly Elected Directors of Sinovac Hold the First Board Meeting

9 Jul

Impact 4 · 12:34 PM

SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board

Impact 4 · 1:17 AM · Business Wire

Sinovac Shareholders Vote to Remove Current Directors and Elect SAIF Partners Nominees to Board at Special Meeting

Impact 4 · 1:05 AM · Business Wire

Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote

Impact 3 · 12:27 PM · Business Wire

SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

Impact 3 · 1:39 AM

SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares

7 Jul

Impact 4 · 1:46 AM · Business Wire

Federal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVAC

Impact 3 · 3:26 PM

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2

3 Jul

Impact 4 · 7:34 PM

Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place

2 Jul

Impact 4 · 10:55 AM · Business Wire

United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac

Impact 4 · 9:20 AM · Business Wire

SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac

Impact 3 · 1:03 AM

Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place

1 Jul

Impact 4 · 3:02 PM · Business Wire

SAIF Partners Sends Letter to Sinovac Shareholders

27 Jun

Impact 4 · 7:12 PM · Business Wire

SINOVAC Board of Directors Prevails Against Advantech/Prime’s Lawsuit in Hong Kong

25 Jun

Impact 4 · 1:41 PM

Seeking a Cure for Sickly Corporate Governance at SinoVac

24 Jun

Impact 4 · 4:13 PM · Business Wire

SAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board’s Failure to Act in the Interests of Shareholders

Impact 4 · 8:27 AM · Business Wire

SINOVAC Board of Directors Files Investor Presentation Outlining Decisive Actions to Protect Shareholder Interests

21 Jun

Impact 4 · 9:20 PM · Business Wire

Prime Success Issues Statement on New York State Court Decision Confirming Our Rights as Sinovac Shareholders – Including Right to Vote at Upcoming Special Meeting

Sinovac Biotech, Ltd.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Sinovac Biotech, Ltd. vs peers (Q) = latest quarter vs a year earlier

Sinovac Biotech, Ltd. (SVA) Latest News

17 Aug

15 Jun

29 May

8 May

6 Feb

22 Jan

4 Jan

17 Dec

18 Nov

11 Nov

24 Oct

11 Jul

10 Jul

9 Jul

7 Jul

3 Jul

2 Jul

1 Jul

27 Jun

25 Jun

24 Jun

21 Jun

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Sinovac Biotech, Ltd. vs peers (Q) = latest quarter vs a year earlier

Sinovac Biotech, Ltd. (SVA) Latest News

17 Aug

15 Jun

29 May

8 May

6 Feb

22 Jan

4 Jan

17 Dec

18 Nov

11 Nov

24 Oct

11 Jul

10 Jul

9 Jul

7 Jul

3 Jul

2 Jul

1 Jul

27 Jun

25 Jun

24 Jun

21 Jun

Stockrow Weekly